Koers NurExone Biologic Inc. Toronto S.E.
Aandelen
ENER
CA29278Q1063
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 31,16 mln. 42,56 mln. 29,1 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -4 mln. -5,46 mln. -3,73 mln. | Nettowinst (verlies) 2025 * | -4 mln. -5,46 mln. -3,73 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-5,26
x | K/w-verhouding 2025 * |
-5,26
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 93,95% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Lior Shaltiel
CEO | Chief Executive Officer | - | 01-04-21 |
Eran Ovadya
DFI | Director of Finance/CFO | - | 15-06-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jay Richardson
BRD | Director/Board Member | 78 | 03-01-22 |
Gadi Riesenfeld
BRD | Director/Board Member | 79 | 06-07-23 |
Yoram Drucker
CHM | Chairman | 59 | 01-01-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+3,13% | 42,11 mld. | |
+48,83% | 40,08 mld. | |
+8,49% | 40 mld. | |
-10,82% | 26,87 mld. | |
+8,26% | 24,58 mld. | |
-23,69% | 18,44 mld. | |
+1,58% | 11,94 mld. | |
+32,83% | 11,66 mld. | |
+6,63% | 11,01 mld. |